1. Home
  2. WLKP vs AKBA Comparison

WLKP vs AKBA Comparison

Compare WLKP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Chemical Partners LP

WLKP

Westlake Chemical Partners LP

HOLD

Current Price

$21.85

Market Cap

756.4M

Sector

Industrials

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.41

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLKP
AKBA
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
756.4M
729.1M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
WLKP
AKBA
Price
$21.85
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.25
AVG Volume (30 Days)
46.7K
3.0M
Earning Date
02-23-2026
03-12-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
N/A
EPS
1.39
N/A
Revenue
$1,133,706,000.00
$225,071,000.00
Revenue This Year
$3.88
$52.38
Revenue Next Year
$12.71
$22.45
P/E Ratio
$15.72
N/A
Revenue Growth
N/A
32.49
52 Week Low
$17.75
$1.30
52 Week High
$25.04
$4.08

Technical Indicators

Market Signals
Indicator
WLKP
AKBA
Relative Strength Index (RSI) 71.84 44.26
Support Level $21.03 $1.37
Resistance Level $21.69 $1.53
Average True Range (ATR) 0.41 0.08
MACD 0.06 0.01
Stochastic Oscillator 75.54 47.83

Price Performance

Historical Comparison
WLKP
AKBA

About WLKP Westlake Chemical Partners LP

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: